There were many encouraging results for the future of lung cancer treatments that emerged from the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting:- Cetuximab (Erbitux) was shown to provide an overall survival benefit in lung cancer when paired with standard chemotherapy.
Intriguing early results suggest that:
- celecoxib (Celebrex) may help to prevent lung cancer in those with a substantial smoking history,
- genetic analysis may predict which early-stage lung cancer patients will benefit from chemotherapy, and
- an investigational drug called CP-751,871 may improve response to chemotherapy.
No comments:
Post a Comment